Rabello-Fonseca R M, Azulay D R, Luiz R R, Mandarim-de-Lacerda C A, Cuzzi T, Manela-Azulay M
Department of Dermatology, Federal University of Rio de Janeiro, Brazil.
J Eur Acad Dermatol Venereol. 2009 Feb;23(2):115-23. doi: 10.1111/j.1468-3083.2008.02947.x. Epub 2008 Sep 22.
Despite evidences of the beneficial clinical effects of oral isotretinoin in the treatment of cutaneous photoaging, scientific evidences are still scarce, mainly supported by histopathological and morphometric studies.
To analyse possible clinical and morphological changes resulting from the treatment of photoaging with oral isotretinoin.
Thirty female patients, aged 40 to 55 years, phototypes II to IV, with moderate to severe photoaging were randomly assigned to two groups of 15 each. Group I (G I) patients were treated with 10 mg of isotretinoin and group II (G II) with 20 mg of oral isotretinoin thrice a week for 3 months. Skin biopsies were performed before and after the end of therapy, and the various sections were submitted to specific staining for collagen and elastic fibres. To analyse the changes, morphometric studies were performed, and the results obtained were analysed by Student's t-test (paired and non-paired). Clinical results of therapy regarding texture, colouring and aspect of the wrinkles were assessed by both physician and patient.
The increase in the amount of collagen fibres was statistically significant with both dosage regimens (mean, 37.8%, increasing to 44.4%; P = 0.029 with the 10-mg dosage; and mean, 36.6%, increasing to 41.9%; P = 0.01 with the 20-mg dosage). A pattern pointing toward a decrease in the number of elastic fibres was found (mean, 15.3-12%; P = 0.014 with the 10-mg dosage; mean, 15.5-14%; P = 0.125 with the 20-mg dosage). Additionally, there was improvement in the general aspect of the skin, regarding texture, wrinkles depth and skin coloration.
Despite ethical considerations, a lack of a control group using placebo may render the results less accurate.
Low dosages of oral isotretinoin seem to be an effective therapeutic option for cutaneous photoaging.
尽管有证据表明口服异维A酸在治疗皮肤光老化方面具有有益的临床效果,但科学证据仍然稀缺,主要以组织病理学和形态计量学研究为支撑。
分析口服异维A酸治疗光老化可能导致的临床和形态学变化。
30名年龄在40至55岁之间、皮肤光类型为II至IV型、患有中度至重度光老化的女性患者被随机分为两组,每组15人。第一组(GI)患者接受10毫克异维A酸治疗,第二组(GII)患者每周三次口服20毫克异维A酸,持续3个月。在治疗开始前和结束后进行皮肤活检,将各个切片进行胶原蛋白和弹性纤维的特异性染色。为了分析变化情况,进行了形态计量学研究,并通过学生t检验(配对和非配对)对所得结果进行分析。医生和患者均对治疗在质地、皱纹颜色和外观方面的临床结果进行评估。
两种剂量方案均使胶原纤维数量增加具有统计学意义(10毫克剂量时,平均值从37.8%增加到44.4%;P = 0.029;20毫克剂量时,平均值从36.6%增加到41.9%;P = 0.01)。发现有弹性纤维数量减少的趋势(10毫克剂量时,平均值从15.3%降至12%;P = 0.014;20毫克剂量时,平均值从15.5%降至14%;P = 0.125)。此外,皮肤在质地、皱纹深度和肤色方面的总体外观有所改善。
尽管考虑了伦理因素,但缺乏使用安慰剂的对照组可能会使结果不够准确。
低剂量口服异维A酸似乎是治疗皮肤光老化的有效治疗选择。